1xbet 로그인 Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee 1xbet 로그인 Medicinal Products 1xbet 로그인 Human Use (CHMP) on 26^thMarch issued a positive opinion (approval in EU) 1xbet 로그인 the new pre-filled dual chamber syringe kit to administer Abilify Maintena® 1xbet 로그인 the maintenance treatment of schizophrenia.

The dual chamber pre-filled syringe is a new addition to the Abilify Maintena offering. Reconstitution occurs within the pre-filled dual chamber syringe, in a single step, which allows 1xbet 로그인 easier handling. This product enhancement offers another option to simplify delivery of care to patients with schizophrenia and provides healthcare professionals with an easier-to-use option.

CHMP positive opinion (approval in EU) of the dual chamber kit follows the recent approval of the deltoid muscle as a new injection site 1xbet 로그인 Abilify Maintena, the latter approval providing patients with a wider range of treatment options.

These new additions to Abilify Maintena are expected to be available 1xbet 로그인 use later in the year.